Evaluation of controlled attenuation parameter in assessing hepatic steatosis in patients with autoimmune liver diseases

Table 1 Baseline patient characteristics

Variable	All (n = 190)	AILDs (n = 114)	NAFLD (n = 66)
Age, yr	46.36 ± 12.82	48.72 ± 11.57	42.15 ± 13.80
Male sex, n (%)	45 (23.68)	23 (20.18)	18 (27.27)
BMI, kg/m2	23.97 ± 2.69	24.33 ± 1.80	23.63 ± 2.34
Prevalence of autoantibodies, n (%)	134 (70.53)	89 (78.07)	37 (56.06)
Laboratory
AST, U/L	63.96 ± 86.42	72.54 ± 102.23	54.6 ± 59.10
ALT, U/L	83.86 ± 86.42	81.98 ± 92.78	92.81 ± 78.67
LDH, U/L	182.70 ± 35.43	183.02 ± 37.39	182.64 ± 32.86
AKP, U/L	80.00 (63.00, 108.50)	85.00 (62.25, 129.5)	75.00 (64.00, 94.00)
GGT, U/L	103.67 ± 126.83	126.00 ± 151.92	76.82 ± 73.15
Total bilirubin, mg/dL	10.90 (8.10, 15.30)	11.20 (8.30, 16.70)	9.80 (6.95, 14.15)
Direct bilirubin, mg/dL	3.60 (2.80, 4.90)	3.70 (2.90, 5.70)	3.45 (2.52, 4.50)
Histological steatosis stage, n (%)
S0 (< 5%)	22 (11.6)	20 (11.1)	0 (0.0)
S1 (5%-33%)	85 (44.7)	61 (33.9)	16 (24.2)
S2 (> 33%-66%)	55 (28.9)	28 (15.6)	27 (40.9)
S3 (> 66%)	28 (14.7)	5 (2.8)	23 (34.8)
Histological fibrosis stage, n (%)
F0 (no fibrosis)	12 (6.3)	1 (0.9)	10 (15.2)
F1 (portal fibrosis without septa)	70 (36.8)	38 (33.3)	30 (45.5)
F2 (portal and periportal fibrosis with few septa)	64 (33.7)	40 (35.1)	18 (27.3)
F3 (portal and periportal fibrosis with numerous septa without cirrhosis)	35 (18.4)	26 (22.8)	8 (12.1)
F4 (cirrhosis)	9 (4.7)	9 (7.9)	0 (0.0)
CAP, dB/m	270.17 ± 54.52	261.73 ± 53.80	290.97 ± 50.68
LSM, kPa	7.66 ± 5.57	8.48 ± 6.50	6.61 ± 3.66

Distributions are expressed as the mean ± SD or median (interquartile range) or number (percentage). AIH: Autoimmune hepatitis; NAFLD: Nonalcoholic fatty liver disease; BMI: Body mass index; AKP: Alkaline phosphatase; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; CAP: Controlled attenuation parameter; GGT: Gamma-glutamyl transferase; LDH: Lactate dehydrogenase; LSM: Liver stiffness measurement.